HOME >> BIOLOGY >> NEWS
Abgenix initiates phase III clinical trial of graft versus host disease therapy

Abgenix to Seek a Corporate Partner to Commercialize ABX-CBL

FREMONT, Calif., December 7, 1999 - Abgenix, Inc. (Nasdaq: ABGX) is initiating a Phase III clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder. Abgenix also indicated that it would seek a corporate partner to assist with the development and commercialization of ABX-CBL.

Abgenix is pursuing the Phase III trial of ABX-CBL based on promising results of a 59 patient Phase II trial of the drug. In that trial, srGVHD patients receiving higher doses of ABX-CBL had more than twice the 180-day survival rate observed in the lowest dose cohort, according to results presented at the annual meeting of the American Society of Hematology (ASH). Survival at 180 days for patients in the higher dose cohorts was 50% versus 22% in the lowest (presumed no effect) dose cohort.

"ABX-CBL demonstrated important clinical benefits as measured by response rate and survival in the Phase II clinical trial," said H. Joachim Deeg, M.D., Department of Transplantation Biology at Fred Hutchinson Cancer Research Center and Principal Investigator for the trial. "Given the limited options available for treating srGVHD patients, ABX-CBL has the potential to be an important new treatment for this disease."

"While we are enthusiastic about ABX-CBL's potential as a much needed treatment for srGVHD, our business strategy is to find corporate partners to commercialize the products we generate," stated R. Scott Greer, president and CEO of Abgenix. "Therefore, we would like to identify a pharmaceutical or biotech company with the development and marketing infrastructure to maximize the commercial potential of ABX-CBL. We plan to begin the Phase III trial on our own, but would like to have a partner on board before it is completed."

GVHD occurs in
'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
6-Dec-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Southern stroke belt study initiates nationwide study
8. Trans-NIH collaboration with NIOSH initiates studies of racial and ethnic disparities in health
9. Gulf of Maine marine ecosystem may have entered new phase
10. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
11. Psoriasis treatment based on Weizmann Institute Research passes phase II clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2019)... ... January 24, 2019 , ... GrowthZone, Inc., ... Survey. The report indicates membership growth in some sectors and decreasing membership among ... received responses from over 500 association professionals across North America. , “This ...
(Date:1/20/2019)... , ... January 16, 2019 , ... ... with doc.ai, a medical research platform that uses artificial intelligence (AI) and a ... supplements for Crohn’s disease and ulcerative colitis. , People will Crohn’s or other ...
(Date:1/14/2019)... (PRWEB) , ... January 14, 2019 , ... ... 2019 at 11am EST (4pm GMT) to hear about key topics in data ... ,     Computer-administered ratings ,     Patient engagement ,     Smartphone and wearable ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... (PRWEB) , ... January 29, 2019 , ... ... Inc. (AskBio), today announced the dosing of the first patient in a phase ... is a serious disease associated with high morbidity and often leads to premature ...
(Date:1/30/2019)... ... January 30, 2019 , ... The Society for Laboratory Automation ... discuss best practices for laboratory automation and screening. This year the conference will ... conference, Visikol will be at booth #345 and throughout the conference will highlight ...
(Date:1/28/2019)... SAN DIEGO (PRWEB) , ... January 28, 2019 ... ... proteins against libraries of low molecular weight compounds. In this early stage, false ... binding. At the same time, it is vital that screening techniques are highly ...
(Date:1/24/2019)... ... January 22, 2019 , ... ... trial has its own set of assumptions, and RFP creation and management generally ... bids is like comparing apples to oranges. These challenges can ultimately lead to ...
Breaking Biology Technology:
Cached News: